SANDOZ TOLTERODINE LA 4 MG
TOLTERODINE TARTRATE : 4 MG · DIN 02413159 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ TOLTERODINE LA?
SANDOZ TOLTERODINE LA 4 MG contains TOLTERODINE TARTRATE : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 02413159, held by SANDOZ CANADA INCORPORATED, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Dec-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ TOLTERODINE LA used for?
Symptomatic management of overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02413159 |
|---|---|
| Brand name | SANDOZ TOLTERODINE LA |
| Generic / active ingredient | TOLTERODINE TARTRATE : 4 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 4 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD07 TOLTERODINE |
| AHFS class | 52:40.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Dec-2015 |
| Original market date | 2014-08-15 00:00:00 |
How is it administered?
Initial maximum dose 4 mg once daily. May be reduced to 2 mg once daily. For hepatic or renal impairment: 2 mg once daily. Swallow whole; can be taken with food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text sections (Table of Contents lists it on page 15, but text ends before page 15).
How is it supplied?
Not explicitly detailed in the provided text (mentions 2 mg and 4 mg strengths).
Contraindications
Urinary retention, gastric retention, uncontrolled narrow angle glaucoma, known hypersensitivity to the drug or any ingredient in the formulation.
Warnings and precautions
Risk of urinary/gastric retention; use caution in patients with controlled narrow angle glaucoma, myasthenia gravis, or QT prolongation. May affect ability to drive/use machinery.
What can be used instead?
Other Canadian products sharing ATC code G04BD07 TOLTERODINE. 14 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DETROL | 1 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02239064 |
| DETROL | 2 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02239065 |
| DETROL LA | 2 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02244612 |
| DETROL LA | 4 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02244613 |
| JAMP TOLTERODINE | 1 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02496836 |
| JAMP TOLTERODINE | 2 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02496844 |
| MINT-TOLTERODINE | 1 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02423308 |
| MINT-TOLTERODINE | 2 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02423316 |
| SANDOZ TOLTERODINE LA | 2 MG | CAPSULE (EXTENDED RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02413140 |
| TEVA-TOLTERODINE | 1 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02299593 |
Who else supplies TOLTERODINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOLTERODINE appears in 76 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.